CN

CN
ABOUT

Immunophage is a clinical-stage biotech company focusing on discovering, developing, and commercializing innovative drugs globally for patients worldwide. The company strengthens its R&D pipeline by continually exploring novel disease pathophysiology, refining new targets, and discovering small-molecule or large-molecule drugs. Immunophage aims to advance two innovative programs into clinical trials by combining internal R&D expertise and partnerships with global biopharmaceutical companies.

View More
  • 2016
    Establishment of the
    company
  • 5
    Number of subsidiaries
    established
  • 3
    Involved in research
    fields
  • 70
    %
    More than 70% of R&D personnel with
    master's degree or above
IMMUNOPHAGE
NEWS

View More

Mar 21, 2023

Immunophage's Second-Tier Global Innovative Drug for IBD Treatment Receives Clinical Trial Approval from the U.S. FDA

View More
CAREERS

Immunophage is a clinical-stage biopharmaceutical company
focused on developing next-generation immunotherapies to benefit
patients worldwide.

View More

Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd All Rights Reserved.